Is Atara Biotherapeutics Stock a Good Investment?
Atara Biotherapeutics Investment Advice | ATRA |
- Examine Atara Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Atara Biotherapeutics' leadership team and their track record. Good management can help Atara Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Atara Biotherapeutics' business and its evolving consumer preferences.
- Compare Atara Biotherapeutics' performance and market position to its competitors. Analyze how Atara Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Atara Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Atara Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Atara Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Atara Biotherapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Atara Biotherapeutics Stock
Researching Atara Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atara Biotherapeutics recorded a loss per share of 25.32. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 20th of June 2024.
To determine if Atara Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atara Biotherapeutics' research are outlined below:
| Atara Biotherapeutics is way too risky over 90 days horizon | |
| Atara Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Atara Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.57 M. Net Loss for the year was (276.13 M) with profit before overhead, payroll, taxes, and interest of 63.57 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Allogeneic T Cell Therapies Market Report, 2024-2028 2033 - Valued at 1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of 1.69 Billion by 2028 |
Atara Biotherapeutics Quarterly Cash And Short Term Investments |
|
Atara Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atara Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atara Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Atara Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Atara Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-09 | 2024-03-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2024-03-28 | 2023-12-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2022-05-05 | 2022-03-31 | -0.98 | -0.87 | 0.11 | 11 | ||
2016-11-04 | 2016-09-30 | -0.77 | -0.88 | -0.11 | 14 | ||
2018-05-08 | 2018-03-31 | -0.92 | -1.05 | -0.13 | 14 | ||
2015-11-05 | 2015-09-30 | -0.56 | -0.43 | 0.13 | 23 | ||
2017-05-04 | 2017-03-31 | -0.74 | -0.88 | -0.14 | 18 | ||
2018-11-06 | 2018-09-30 | -1.13 | -1.29 | -0.16 | 14 |
Know Atara Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atara Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atara Biotherapeutics backward and forwards among themselves. Atara Biotherapeutics' institutional investor refers to the entity that pools money to purchase Atara Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Centiva Capital Lp | 2024-09-30 | 43.4 K | Staley Capital Advisers Inc | 2024-09-30 | 40 K | Fmr Inc | 2024-09-30 | 25.1 K | State Street Corp | 2024-09-30 | 22.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 16.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 14 K | Jpmorgan Chase & Co | 2024-09-30 | 1.4 K | Wells Fargo & Co | 2024-09-30 | 1.3 K | Tower Research Capital Llc | 2024-09-30 | 752 | Ecor1 Capital, Llc | 2024-09-30 | 468.9 K | Redmile Group, Llc | 2024-09-30 | 452.3 K |
Atara Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.78 M.Market Cap |
|
Atara Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.67) | (1.75) | |
| Return On Capital Employed | (11.86) | (11.26) | |
| Return On Assets | (1.67) | (1.75) | |
| Return On Equity | 2.78 | 2.92 |
Determining Atara Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Atara Biotherapeutics is a good buy. For example, gross profit margin measures Atara Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Atara Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Evaluate Atara Biotherapeutics' management efficiency
Atara Biotherapeutics has return on total asset (ROA) of (0.5748) % which means that it has lost $0.5748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 2.92, whereas Return On Tangible Assets are forecasted to decline to (1.75). At present, Atara Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.1 M, whereas Non Current Assets Total are forecasted to decline to about 44.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (23.42) | (22.25) | |
| Tangible Book Value Per Share | (23.42) | (22.25) | |
| Enterprise Value Over EBITDA | (0.32) | (0.34) | |
| Price Book Value Ratio | (0.55) | (0.57) | |
| Enterprise Value Multiple | (0.32) | (0.34) | |
| Price Fair Value | (0.55) | (0.57) | |
| Enterprise Value | 99.3 M | 86.6 M |
The strategic initiatives led by Atara Biotherapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.495 |
Basic technical analysis of Atara Stock
As of the 26th of December, Atara Biotherapeutics shows the risk adjusted performance of 0.1478, and Mean Deviation of 4.51. Atara Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Atara Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atara Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atara Biotherapeutics' Outstanding Corporate Bonds
Atara Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atara Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atara bonds can be classified according to their maturity, which is the date when Atara Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ATT INC 535 Corp BondUS04650NAB01 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Atara Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Atara Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1478 | |||
| Market Risk Adjusted Performance | 0.5177 | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 4.13 | |||
| Downside Deviation | 4.81 | |||
| Coefficient Of Variation | 575.03 | |||
| Standard Deviation | 6.26 | |||
| Variance | 39.19 | |||
| Information Ratio | 0.1668 | |||
| Jensen Alpha | 1.0 | |||
| Total Risk Alpha | 0.8067 | |||
| Sortino Ratio | 0.2171 | |||
| Treynor Ratio | 0.5077 | |||
| Maximum Drawdown | 32.64 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 11.98 | |||
| Downside Variance | 23.12 | |||
| Semi Variance | 17.08 | |||
| Expected Short fall | (5.39) | |||
| Skewness | 1.0 | |||
| Kurtosis | 1.97 |
| Risk Adjusted Performance | 0.1478 | |||
| Market Risk Adjusted Performance | 0.5177 | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 4.13 | |||
| Downside Deviation | 4.81 | |||
| Coefficient Of Variation | 575.03 | |||
| Standard Deviation | 6.26 | |||
| Variance | 39.19 | |||
| Information Ratio | 0.1668 | |||
| Jensen Alpha | 1.0 | |||
| Total Risk Alpha | 0.8067 | |||
| Sortino Ratio | 0.2171 | |||
| Treynor Ratio | 0.5077 | |||
| Maximum Drawdown | 32.64 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 11.98 | |||
| Downside Variance | 23.12 | |||
| Semi Variance | 17.08 | |||
| Expected Short fall | (5.39) | |||
| Skewness | 1.0 | |||
| Kurtosis | 1.97 |
Consider Atara Biotherapeutics' intraday indicators
Atara Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atara Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Atara Biotherapeutics Corporate Filings
8K | 23rd of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 5th of September 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Atara Stock media impact
Far too much social signal, news, headlines, and media speculation about Atara Biotherapeutics that are available to investors today. That information is available publicly through Atara media outlets and privately through word of mouth or via Atara internal channels. However, regardless of the origin, that massive amount of Atara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Atara Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Atara Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Atara Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Atara Biotherapeutics alpha.
Atara Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Atara Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Atara Biotherapeutics Corporate Management
| Rajani MD | Senior Officer | Profile | |
| Eric Hyllengren | Executive Officer | Profile | |
| Jakob MD | Ex RD | Profile | |
| Kerry Daly | Head Communications | Profile | |
| Jill Henrich | Executive Quality | Profile | |
| Utpal MBA | Ex CFO | Profile | |
| Alex Chapman | Vice Relations | Profile |
Already Invested in Atara Biotherapeutics?
The danger of trading Atara Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atara Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atara Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atara Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Atara Biotherapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.